HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew N Gifford Selected Research

2- iodophenyl- (1- (1- methylpiperidin- 2- ylmethyl)- 1H- indol- 3- yl)methanone

8/2006Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew N Gifford Research Topics

Disease

1Parkinson Disease (Parkinson's Disease)
12/2017
1Pancreatic Diseases (Pancreatic Disease)
09/2008
1Alcoholism (Alcohol Abuse)
09/2008
1Catalepsy
08/2006

Drug/Important Bio-Agent (IBA)

1Phosphotransferases (Kinase)IBA
12/2017
1Leucine (L-Leucine)FDA Link
12/2017
1Pharmaceutical PreparationsIBA
12/2017
1Ethanol (Ethyl Alcohol)IBA
09/2008
1CB1 Cannabinoid Receptor (CB1 Receptor)IBA
08/2006
12- iodophenyl- (1- (1- methylpiperidin- 2- ylmethyl)- 1H- indol- 3- yl)methanoneIBA
08/2006
1RimonabantIBA
08/2006
1(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA
08/2006